PharmaDrug Inc.: PharmaDrug Successfully Completes Key Milestone to Support cGMP Production of Clinical Lead Candidate PD-001, Its Patented, Orally Available Version of Cepharanthine for Oncology and Infectious Disease

Completes qualification of all necessary analytical methodologies to support production of Cepharanthine-2HCL drug substanceClinical trial-scale production of cGMP Cepharanthine-2HCL drug substance scheduled

Related Keywords

Saijo ,Tokushima ,Japan ,United States ,Akanaya ,Wakayama ,South Africa ,Toronto ,Ontario ,Canada ,Chikita ,Fukui ,Dejima ,Japan General ,Canadian ,South African ,Wangy Cepharanthine ,Daniel Cohen ,Baillyc Cepharanthine ,Newsfile Corp ,Development Paths For Oncology ,Pharmadrug Inc ,Drug Administration ,Genvion Corporation ,Development Paths ,Infectious Disease Create ,Enteric Coated Oral Cepharanthine ,Validated Studies Reveal Potential ,Enabling Prostate Cancer ,Enabling Esophageal Cancer ,Drug Designation ,Infectious Disease ,Middle East ,Cepharanthine May Work ,Block Coronavirus ,Sairiyo Therapeutics ,Super Smart ,Regarding Forward Looking Information ,Drug Repurposing Screens ,Pharmadrug ,Uccessfully ,Ompletes ,Milestone ,Support ,Gmp ,Production ,Linical ,Head ,Candidate ,Atented ,Rally ,Vailable ,Version ,Cepharanthine ,Ncology ,Nfectious ,Disease ,